Seattle Genetics, OBT sign deal to develop ADCs for cancer
The agreement allows OBT to develop a range of monoclonal antibodies targeting novel tumor-specific antigens identified using its proprietary Oxford Genome Anatomy Project (OGAP) database. The antibodies generated
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.